Francis Wheeler

Cooley represented Beta Bionics, a pioneering leader in the development of advanced diabetes management solutions, in its $234.6 million initial public offering and concurrent $17 million private placement.

Cooley advised Tvardi Therapeutics, a privately held, clinical-stage biopharmaceutical company focused on the development of novel, oral, small-molecule therapies targeting STAT3 to treat fibrosis-driven diseases, on its definitive merger agreement to combine in an all-stock transaction with Cara Therapeutics (Nasdaq: CARA), a development-stage biopharmaceutical company that has been leading a new treatment paradigm to improve the lives of patients suffering from pruritus.

Cooley advised Vance Street Capital, a Los Angeles-based middle-market private equity firm that invests in highly engineered solutions businesses across the industrial technology, medical, life sciences, aerospace and defense sectors, on its acquisition of System Seals, a designer and manufacturer of custom fluid seals for various industrial applications.

Cooley advised Core Scientific (NASDAQ: CORZ), a leader in digital infrastructure for bitcoin mining and high-performance computing, on its $625 million aggregate principal of 0.00% convertible senior notes due 2031, which includes the exercise in full of the initial purchasers’ option to purchase up to an additional $75 million aggregate principal amount of notes.

Cooley advised Aclaris Therapeutics (Nasdaq: ACRS), a clinical-stage biopharmaceutical company developing novel drug candidates for immuno-inflammatory diseases, on its exclusive license agreement with Biosion and $80 million private placement.